Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Viridian Therapeutics ( (VRDN) ) just unveiled an announcement.
On July 30, 2025, Viridian Therapeutics announced a collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize veligrotug and VRDN-003 in Japan. The agreement includes an upfront payment of $70 million to Viridian, with potential additional milestone payments up to $315 million and tiered royalties on net sales. This partnership combines Viridian’s expertise in thyroid eye disease treatments with Kissei’s experience in rare diseases, aiming to address unmet needs for TED patients in Japan.
The most recent analyst rating on (VRDN) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Viridian Therapeutics stock, see the VRDN Stock Forecast page.
Spark’s Take on VRDN Stock
According to Spark, TipRanks’ AI Analyst, VRDN is a Neutral.
The overall stock score of 61 reflects the mixed outlook for Viridian Therapeutics. The most significant strength is the positive phase 3 trial results, which boost potential future growth. However, financial instability due to declining revenues and negative profitability weigh heavily on the score. Technical indicators suggest current positive momentum, but valuation remains unattractive due to negative earnings.
To see Spark’s full report on VRDN stock, click here.
More about Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. The company specializes in antibody discovery and protein engineering, advancing multiple candidates for the treatment of thyroid eye disease (TED) and a novel portfolio of neonatal Fc receptor inhibitors for autoimmune diseases. Viridian is based in Waltham, Massachusetts.
Average Trading Volume: 742,429
Technical Sentiment Signal: Buy
Current Market Cap: $1.41B
For detailed information about VRDN stock, go to TipRanks’ Stock Analysis page.